Immunomedics
- Properties2FY, 2019
- Revenue$295 KFY, 2019
- Market Capitalization$20.3 B2020-10-26
OverviewSuggest Edit
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow creating humanized antibodies that can be used either alone in unlabeled or naked form or conjugated with radioactive isotopes, chemotherapeutics, cytokines, or toxins.
| Type | Public | |
| Founded | 1982 | |
| HQ | Morris Plains, NJ, US | Map |
| Website | immunomedics.com | |
| Employee Ratings |
Recent NewsAll News
- Global Antibody Drug Conjugates Market Research 2021 Featuring Major Players - Bayer, Concortis Biotherapeutics, F. Hoffman-La Roche, Immunomedics, and Oxford BioTherapeutics
- Portnoy Law Firm: Tactile Systems Technology, Inc., Pintec Technologies Holdings Limited, and Immunomedics, Inc. Investors Have Limited Amount of Time Before Class Action Deadline
- Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma
- Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
Key People/Management at Immunomedics
Behzad Aghazadeh
Executive Chairman of the Board of Directors
Usama Malik
Chief Financial Officer, Chief Business Officer
Brendan Delaney
Chief Commercial Officer
Kurt Andrews
Chief Human Resources Officer
Jared Freedberg
General Counsel and Corporate Secretary
Bryan Ball
Chief Quality Officer
Immunomedics Office Locations
Immunomedics has offices in Morris Plains and Rödermark
Morris Plains, NJ, US (HQ)
300 The American Rd
Rödermark, DE
Paul-Ehrlich-Straße 22/D1
Immunomedics Financials and Metrics
Immunomedics Revenue
Immunomedics's revenue was reported to be $295 k in FY, 2019 which is a 86.3% decrease from the previous period.
| USD | |
|---|---|
Revenue (Q2, 2020) | 20.1m |
Gross profit (Q2, 2020) | 18.4m |
Gross profit margin (Q2, 2020), % | 91.7% |
Net income (Q2, 2020) | (66.5m) |
EBIT (Q2, 2020) | (53.0m) |
Market capitalization (26-Oct-2020) | 20.3b |
Closing stock price (26-Oct-2020) | 87.9 |
Cash (30-Jun-2020) | 971.2m |
EV | 19.3b |
Immunomedics's current market capitalization is $20.3 b.
Annual
Half Year
| USD | H2, 2018 |
|---|---|
Sales and marketing expense | 19.8m |
Annual
Annual
| USD | FY, 2017 |
|---|---|
Revenue/Employee | 23.6k |
Debt/Equity | -3.2 x |
Debt/Assets | 1.2 x |
Financial Leverage | -2.7 x |
Immunomedics Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| IBC Pharmaceuticals, Inc. | ||
| Immunomedics GmbH |
Immunomedics Revenue Breakdown
Immunomedics revenue breakdown by business segment: 15.3% from License fee and other revenues, 15.1% from Research and development and 69.6% from Product sales
Immunomedics Cybersecurity Score
Immunomedics Environment, Social & Governance (ESG) Ratings
Immunomedics Online and Social Media Presence
581 Twitter followers
Immunomedics has 581 Twitter Followers. The number of followers has decreased 0.4% month over month and decreased 1.3% quarter over quarter
Immunomedics's Trends
Immunomedics News and Updates
October 20, 2021
Global Antibody Drug Conjugates Market Research 2021 Featuring Major Players - Bayer, Concortis Biotherapeutics, F. Hoffman-La Roche, Immunomedics, and Oxford BioTherapeutics
Dublin, Oct. 20, 2021 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. The global antibody drug conjugates market is expected to grow from $2.34 billion in 2020 to $2.6 billi…
November 27, 2020
Portnoy Law Firm: Tactile Systems Technology, Inc., Pintec Technologies Holdings Limited, and Immunomedics, Inc. Investors Have Limited Amount of Time Before Class Action Deadline
Investors with losses are encouraged to contact Attorney Lesley F. Portnoy. Investors with losses are encouraged to contact Attorney Lesley F. Portnoy.
October 12, 2020
Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma
MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administ…
September 19, 2020
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC)
September 19, 2020
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Immunomedics, Inc. - IMMU
NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Immunomedics, Inc. ("Immunomedics" or the "Company") (IMMU)...
September 18, 2020
Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers
Results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM) Results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM)
Immunomedics Blogs
February 08, 2021
Head of Quality
Head of Quality
Anonymous (not verified)
Mon, 02/08/2021 - 18:08
1773
GxP Quality & Compliance
Full-Time Exempt Salary (30+ Hours)
Apply Now
US - NJ - Morris Plains
1 month ago
…
February 08, 2021
Director, Site Supply Chain
Director, Site Supply Chain
Anonymous (not verified)
Mon, 02/08/2021 - 18:08
1771
Supply Chain
Full-Time Exempt Salary (30+ Hours)
Apply Now
US - NJ - Morris Plains
1 month ago
…
February 01, 2021
Medical Science Liaison - MSL - (NY/NJ) - Oncology
Medical Science Liaison - MSL - (NY/NJ) - Oncology
Anonymous (not verified)
Mon, 02/01/2021 - 17:25
1756
Medical Affairs
Full-Time Non-Exempt Hourly (30+ Hours)
Apply Now
US - NY
3 months ago
…
January 21, 2021
Associate Director, CMC Regulatory Affairs - Biologics
Associate Director, CMC Regulatory Affairs - Biologics
Anonymous (not verified)
Thu, 01/21/2021 - 16:36
1757
Regulatory
Full-Time Exempt Salary (30+ Hours)
Apply Now
US - NJ - Morris Plains
3 …
January 12, 2021
Quality Control Scientist
Quality Control Scientist
Anonymous (not verified)
Tue, 01/12/2021 - 15:42
1767
GxP Quality & Compliance
Full-Time Exempt Salary (30+ Hours)
Apply Now
US - NJ - Morris Plains
4 weeks ago
…
January 06, 2021
Oncology Account Manager - Pittsburgh
Oncology Account Manager - Pittsburgh
Anonymous (not verified)
Wed, 01/06/2021 - 15:18
1763
Sales
Full-Time Exempt Salary (30+ Hours)
Apply Now
US - PA - Pittsburgh
1 month ago
…
Immunomedics Frequently Asked Questions
When was Immunomedics founded?
Immunomedics was founded in 1982.
Who are Immunomedics key executives?
Immunomedics's key executives are Behzad Aghazadeh, Usama Malik and Brendan Delaney.
How many employees does Immunomedics have?
Immunomedics has 366 employees.
What is Immunomedics revenue?
Latest Immunomedics annual revenue is $295 k.
What is Immunomedics revenue per employee?
Latest Immunomedics revenue per employee is $806.
Who are Immunomedics competitors?
Competitors of Immunomedics include Novartis, ImmunoGen and AstraZeneca.
Where is Immunomedics headquarters?
Immunomedics headquarters is located at 300 The American Rd, Morris Plains.
Where are Immunomedics offices?
Immunomedics has offices in Morris Plains and Rödermark.
How many offices does Immunomedics have?
Immunomedics has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies